At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 223 enrolled
Drug / intervention
Epoetin alfadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions
In Brief
A Phase 2 clinical trial evaluating Epoetin alfa for Acute ST Elevation Myocardial Infarction. Completed, enrolled 223 participants across 16 sites.
Detailed Summary
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute ST Elevation Myocardial Infarction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedSep 2006
Primary CompletionJul 2009
Study CompletionJan 2011
TodayJul 2026
First PostedSep 20, 2006
Enrollment StartSep 1, 2005
Primary CompletionJul 1, 2009
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 19.8 years ago
Interventions
Epoetin alfadrug
Randomized